Five Prime Therapeutics Inc.
www.fiveprime.com
Latest From Five Prime Therapeutics Inc.
Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses
Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.
Appointments: Roche, Eli Lilly, Ipsen And Syros Make New Leadership Hires, Plus Board Appointments At EUSA, Autolus And Forendo
The latest biopharma industry personnel moves include a new executive hires at Roche, Lilly Oncology, Ipsen and Syros, a resignation at Five Prime, plus new board appointments at EUSA, Autolus and Forendo.
Deals Shaping The Medical Industry, February 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Moderna raised $500m to fund its growing pipeline, choosing once again to stay private rather than pursue an IPO. Also, AvroBio closed a $60m Series B round to advance its gene therapies for lysosomal storage disorders, Seattle Genetics led recent public company financings, and Vical is restructuring.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Immune Disorders
- Alias(es)
- FivePrime Therapeutics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Five Prime Therapeutics Inc.
- Senior Management
-
Lewis T Williams, MD, PhD, Pres. & CEO
Aron Knickerbocker, COO
Francis Sarena, Chief Strategy Officer
Helen Collins, MD, SVP, CMO
Bryan Irving, PhD, SVP, Research - Contact Info
-
Five Prime Therapeutics Inc.
Phone: (415) 365-5600
111 Oyster Point Blvd.
South San Francisco, CA 94080
USA
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice